Gestational obesity: An unconventional endocrine disruptor for the fetus.

Biochemical pharmacology 2022 Apr

filter terms:

Obesity has reached pandemic proportions and is a growing concern throughout the world. A parallel trend has also been observed among women in reproductive age, leading to the increasing global prevalence of gestational obesity (GO). The well-known obesity-related health problems also extend to pregnancy, where they are responsible for giving rise to a variety of medical and obstetrical complications, resulting in an increased incidence of adverse maternal and fetal outcomes. In this context, several epidemiological and clinical studies have shown that nutritional changes through different stages of gestation can have a substantial impact on the future health and development of the child. Therefore, it is clear that GO is a modifiable endocrine disruptor that negatively influences the health of the fetus and the newborn, with long-term metabolic implications. This review aims to describe the impact of GO on maternal and fetal outcomes using the available scientific literature and highlighting the evidence-based nutritional approaches currently recommended for the management of GO. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Luigi Barrea, Claudia Vetrani, Ludovica Verde, Evelyn Frias-Toral, Eloisa Garcia-Velasquez, Priyanga Ranasinghe, Verna Mendez, Ranil Jayawardena, Silvia Savastano, Annamaria Colao, Giovanna Muscogiuri. Gestational obesity: An unconventional endocrine disruptor for the fetus. Biochemical pharmacology. 2022 Apr;198:114974